-
Mashup Score: 6Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV - 6 month(s) ago
Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV @GhaithAbuZeinah @WeillCornell @BloodAdvances #mpnsm #oncology https://t.co/nApWh7RnYu
-
-
Mashup Score: 1Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV - 7 month(s) ago
Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV @GhaithAbuZeinah @WeillCornell @BloodAdvances #mpnsm #oncology https://t.co/nApWh7RnYu
-
-
Mashup Score: 3European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS - 8 month(s) ago
The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS #mpnsm #oncology https://t.co/gwyMH1IiS5
-
-
Mashup Score: 3European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS - 8 month(s) ago
The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS #mpnsm #oncology https://t.co/gwyMH1IiS5
-
-
Mashup Score: 1Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN - 8 month(s) ago
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation. #mpnsm #oncology https://t.co/d88AD6P9eF
-
-
Mashup Score: 3Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis - 8 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis #mpnsm #oncology https://t.co/q2AYoDOIhj
-
-
Mashup Score: 1Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN - 8 month(s) ago
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation. #mpnsm #oncology https://t.co/d88AD6P9eF
-
-
Mashup Score: 3Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances - 8 month(s) ago
Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Newer-generation JAK inhibitors are increasingly adept at controlling symptoms in patients with myelofibrosis and may recapture treatment response in patients who have progressed on prior ruxolitinib. @columbiacancer #mpnsm #oncology https://t.co/oB7labhKeT https://t.co/RyG8PIR9M6
-
-
Mashup Score: 3Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis - 8 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis #mpnsm #oncology https://t.co/q2AYoDOIhj
-
Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis @AshKishtagari @VUMC_Cancer #mpnsm #oncology https://t.co/yU5jEW4UIA